View Future GrowthIMV 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 IMV 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.모든 업데이트 보기Recent updates공시 • Sep 23IMV Inc. Files Form 15IMV Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.공시 • Jul 08Nasdaq to Delist the Common Shares of IMVNasdaq announced on July 06, 2023 that it will delist the common shares of IMV Inc. The company’s securities were suspended on May 11, 2023, and have not traded on Nasdaq since that time.공시 • May 12IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite IndexIMV Inc. has been added to NASDAQ Composite Index (^COMP).공시 • May 09IMV Receives Nasdaq Delisting NoticeIMV Inc. (the “Company” or “IMV”) announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”). The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).공시 • Feb 14IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize TrialIMV Inc. announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL"). Overall Response Rate ("ORR") will be communicated when the totality of stage one data are available for definitive assessment.Board Change • Jan 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Saman Maleki was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 09IMV Inc. Announces Board ChangesIMV Inc. announced the appointment of Shabnam Kazmi to the Board of Directors. Ms. Kazmi is an experienced CEO and Founder with over 30 years experience in top-tier global biopharma companies such as Bristol-Myers Squibb, Sanofi and Otsuka America Pharmaceuticals. She has deep expertise in oncology, having launched and managed multiple top tier products across both solid tumors and hematology. She currently serves as the CEO of Asellus Ventures, a healthcare advisory and investment firm. She has led multiple global joint ventures and successfully managed large complex projects across 75 countries with a focus on managing risk and creating asset value. Ms. Kazmi has consistently achieved outstanding financial results and growth in value for shareholders by managing $1B+ P&Ls, developing innovative strategies, M&A, building highly talented teams, raising capital, and successfully launching and commercializing oncology products for the treatment of both solid tumors and hematology. Her passion for patients and over 20 years of board service has led to multiple awards from cancer patient groups, and she currently serves as a Board Member of the Prevent Cancer Foundation. Ms. Kazmi has a Bachelor’s degree in Economics and Biochemistry from Smith College and an MBA from Harvard Business School. Ms. Kazmi’s appointment follows the decision of Ms. Julia P. Gregory who has served on IMV's Board of Directors since June 2018, to retire from the Board of Directors.Seeking Alpha • Sep 15IMV to cut ~33% workforce amid reorganizationIMV (NASDAQ:IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV intends to focus its resources on ongoing MVP-S clinical programs in immuno-oncology (IO), notably phase 2b trials VITALIZE in relapsed/ refractory Diffuse Large B Cell Lymphoma (DLBCL) and AVALON for advanced metastatic ovarian cancer. In addition, the Canadian company said that Saman Maleki was appointed to the board replacing Brittany Davison who will be promoted to chief accounting officer from her current role as senior vice president, Finance. Maleki is an Assistant Professor of Oncology, Pathology & Laboratory Medicine, and Medical Biophysics at Western University and is an expert in the field of immuno-oncology, according to IMV. IMV +4.05% to $0.77 premarket Sept. 15Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Jul 08IMV receives Nasdaq non-compliance letterIMV (NASDAQ:IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance.Board Change • Jul 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.Executive Departure • Aug 05CEO & Director Frederic Ors has left the companyDuring their tenure, earnings grew by 32% annually compared to the industry average of 23%. On the 1st of August, Frederic Ors left the company after 5.3 in the role. As of March 2021, Frederic still personally held 301.47k shares (US$1.0m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Frederic's leadership, the company delivered a total shareholder return of 21%.Board Change • Jul 31High number of new directorsIndependent Director Kyle Kuvalanka was the last director to join the board, commencing their role in 2021.Recent Insider Transactions • Jul 25CEO & Director recently bought US$147k worth of stockOn the 23rd of July, Frederic Ors bought around 100k shares on-market at roughly US$1.47 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of US$195k worth in shares.Executive Departure • Jun 15Chief Medical Officer Joanne Schindler has left the companyOn the 11th of June, Joanne Schindler's tenure as Chief Medical Officer ended after 1.6 years in the role. We don't have any record of a personal shareholding under Joanne's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Apr 07Independent Director has left the companyOn the 1st of April, Wayne Pisano's tenure as Independent Director ended after 9.5 years in the role. As of December 2020, Wayne personally held 77.28k shares (US$238k worth at the time). Wayne is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 05New 90-day high: US$4.36The company is up 18% from its price of US$3.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$16.30 per share.Is New 90 Day High Low • Dec 19New 90-day low: US$3.13The company is down 37% from its price of US$4.97 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$13.97 per share.Analyst Estimate Surprise Post Earnings • Nov 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates by 12%.Is New 90 Day High Low • Oct 27New 90-day low: US$3.15The company is down 36% from its price of US$4.95 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.95 per share.Is New 90 Day High Low • Oct 12New 90-day low: US$3.85The company is down 17% from its price of US$4.63 on 14 July 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.25 per share.매출 및 비용 세부 내역IMV가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:IMVI.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 220-3817030 Sep 220-4117030 Jun 220-4318031 Mar 220-4017031 Dec 210-3716030 Sep 210-3215030 Jun 210-2813031 Mar 210-2612031 Dec 200-2611030 Sep 200-2510030 Jun 200-249031 Mar 200-228031 Dec 190-218030 Sep 190-207030 Jun 190-197031 Mar 190-197031 Dec 180-167030 Sep 180-157030 Jun 180-126031 Mar 180-105031 Dec 170-105030 Sep 170-94030 Jun 170-84-131 Mar 170-73-131 Dec 160-73030 Sep 160-63130 Jun 160-63331 Mar 160-73431 Dec 150-63330 Sep 150-633양질의 수익: IMVI.F가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 IMVI.F의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 IMVI.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: IMVI.F의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: IMVI.F의 지난 해 수익 증가율이 Biotechs 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: IMVI.F는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 17:03종가2026/05/22 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스IMV Inc.는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sarah ChiassonBeacon Securities LimitedMayank MamtaniB. Riley Securities, Inc.Thomas ShraderBTIG5명의 분석가 더 보기
Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
공시 • Sep 23IMV Inc. Files Form 15IMV Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.
공시 • Jul 08Nasdaq to Delist the Common Shares of IMVNasdaq announced on July 06, 2023 that it will delist the common shares of IMV Inc. The company’s securities were suspended on May 11, 2023, and have not traded on Nasdaq since that time.
공시 • May 12IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite IndexIMV Inc. has been added to NASDAQ Composite Index (^COMP).
공시 • May 09IMV Receives Nasdaq Delisting NoticeIMV Inc. (the “Company” or “IMV”) announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”). The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).
공시 • Feb 14IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize TrialIMV Inc. announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL"). Overall Response Rate ("ORR") will be communicated when the totality of stage one data are available for definitive assessment.
Board Change • Jan 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Saman Maleki was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 09IMV Inc. Announces Board ChangesIMV Inc. announced the appointment of Shabnam Kazmi to the Board of Directors. Ms. Kazmi is an experienced CEO and Founder with over 30 years experience in top-tier global biopharma companies such as Bristol-Myers Squibb, Sanofi and Otsuka America Pharmaceuticals. She has deep expertise in oncology, having launched and managed multiple top tier products across both solid tumors and hematology. She currently serves as the CEO of Asellus Ventures, a healthcare advisory and investment firm. She has led multiple global joint ventures and successfully managed large complex projects across 75 countries with a focus on managing risk and creating asset value. Ms. Kazmi has consistently achieved outstanding financial results and growth in value for shareholders by managing $1B+ P&Ls, developing innovative strategies, M&A, building highly talented teams, raising capital, and successfully launching and commercializing oncology products for the treatment of both solid tumors and hematology. Her passion for patients and over 20 years of board service has led to multiple awards from cancer patient groups, and she currently serves as a Board Member of the Prevent Cancer Foundation. Ms. Kazmi has a Bachelor’s degree in Economics and Biochemistry from Smith College and an MBA from Harvard Business School. Ms. Kazmi’s appointment follows the decision of Ms. Julia P. Gregory who has served on IMV's Board of Directors since June 2018, to retire from the Board of Directors.
Seeking Alpha • Sep 15IMV to cut ~33% workforce amid reorganizationIMV (NASDAQ:IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV intends to focus its resources on ongoing MVP-S clinical programs in immuno-oncology (IO), notably phase 2b trials VITALIZE in relapsed/ refractory Diffuse Large B Cell Lymphoma (DLBCL) and AVALON for advanced metastatic ovarian cancer. In addition, the Canadian company said that Saman Maleki was appointed to the board replacing Brittany Davison who will be promoted to chief accounting officer from her current role as senior vice president, Finance. Maleki is an Assistant Professor of Oncology, Pathology & Laboratory Medicine, and Medical Biophysics at Western University and is an expert in the field of immuno-oncology, according to IMV. IMV +4.05% to $0.77 premarket Sept. 15
Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Jul 08IMV receives Nasdaq non-compliance letterIMV (NASDAQ:IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance.
Board Change • Jul 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 18Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
Executive Departure • Aug 05CEO & Director Frederic Ors has left the companyDuring their tenure, earnings grew by 32% annually compared to the industry average of 23%. On the 1st of August, Frederic Ors left the company after 5.3 in the role. As of March 2021, Frederic still personally held 301.47k shares (US$1.0m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Frederic's leadership, the company delivered a total shareholder return of 21%.
Board Change • Jul 31High number of new directorsIndependent Director Kyle Kuvalanka was the last director to join the board, commencing their role in 2021.
Recent Insider Transactions • Jul 25CEO & Director recently bought US$147k worth of stockOn the 23rd of July, Frederic Ors bought around 100k shares on-market at roughly US$1.47 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of US$195k worth in shares.
Executive Departure • Jun 15Chief Medical Officer Joanne Schindler has left the companyOn the 11th of June, Joanne Schindler's tenure as Chief Medical Officer ended after 1.6 years in the role. We don't have any record of a personal shareholding under Joanne's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Apr 07Independent Director has left the companyOn the 1st of April, Wayne Pisano's tenure as Independent Director ended after 9.5 years in the role. As of December 2020, Wayne personally held 77.28k shares (US$238k worth at the time). Wayne is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 19Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019)Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 05New 90-day high: US$4.36The company is up 18% from its price of US$3.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$16.30 per share.
Is New 90 Day High Low • Dec 19New 90-day low: US$3.13The company is down 37% from its price of US$4.97 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$13.97 per share.
Analyst Estimate Surprise Post Earnings • Nov 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates by 12%.
Is New 90 Day High Low • Oct 27New 90-day low: US$3.15The company is down 36% from its price of US$4.95 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.95 per share.
Is New 90 Day High Low • Oct 12New 90-day low: US$3.85The company is down 17% from its price of US$4.63 on 14 July 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.25 per share.